Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could half the magnesium dose after delivery be just as safe?

NCT ID NCT00344058

Disease control Sponsor: Case Western Reserve University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether giving magnesium sulfate for 12 hours after delivery instead of the usual 24 hours is safe and effective for preventing seizures in women with mild preeclampsia. Researchers enrolled 200 women and compared the two treatment lengths. The goal was to see if a shorter treatment could reduce side effects and hospital time without increasing risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
magnesium sulfate
What this could lead to
If successful, this could show that a shorter course of magnesium sulfate is just as effective, reducing hospital stays and side effects for women with mild preeclampsia.
What could go wrong
This is a small, completed study focused on mild cases only. Results may not apply to severe preeclampsia or preterm deliveries, and the shorter regimen might not prevent seizures in all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

Started

Jan 2001

Finished

Aug 2004

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women with suspected mild preeclampsia diagnosed antepartum, intrapartum, or post-partum were eligible for inclusion after delivery at term (≥ 34 weeks' gestational age). Exclusion Criteria: * Inability to give informed consent, preterm delivery, severe preeclampsia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild preeclampsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mild pre-eclampsia preeclampsia eclampsia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Preeclampsia Pregnancy

Contacts and locations

Locations

  • MetroHealth Medical Center, Labor and Delivery

    Cleveland, Ohio, 44109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.